
Only 0.5% of 90,000 oil slicks reported over five-year period, analysis finds
The figure, obtained from Lloyd's List by the Guardian and Watershed Investigations, shows the pollution incidents reported between 2014 and 2019, compared against a scientific study using satellite imagery that counted the number of slicks from ships over the same period.
Furthermore, all oil slicks from ships visible by satellites are illegal because they exceed pollution limits by at least three orders of magnitude, new research by Florida State University has found. Many of the slicks are the result of ships deliberately discharging bilge water containing oil in order to keep the vessels stable.
'The level of under-reporting of pollution is a huge unknown,' Dr Elizabeth Atwood from Plymouth Marine Laboratory said. 'The argument that has historically been made is that there is an equal amount coming from natural seeps. But recent research keeps underlining that this is not true for much of the globe,' said Atwood.
Hugo Tagholm, the executive director of Oceana UK, said: 'It is appalling to hear of the extreme levels of toxic pollution caused by these oil spills from shipping, as well as the frankly mind-bending under-reporting of the situation.'
Extensive analysis by scientists of hundreds of thousands of satellite images of slicks in the world's seas between 2014 and 2019, found that 20% – or 90,411 – originated from ships and added up to about the size of Italy, with 21 high-density slick belts coinciding with shipping routes. In comparison, 2% were from oil platforms and pipelines, and just over 6% from natural oil seeps on the ocean floor. The rest were either from land sources or unidentified ships.
'Our data show that these spills represent persistent and widespread violations,' said Ian MacDonald, a retired professor of oceanography from Florida State University and coauthor of the paper.
The researchers say this is the first time that real world data has proven that properly treated discharges do not leave a visible trace.
'It suggests that bilge dumping has been a pervasive issue in the global oceans for decades,' said Carrie O'Reilly, the lead author at Florida State University.
Yet only a fraction of these pollution incidents have faced any sanction under the international convention for the prevention of pollution from ships (Marpol).
'It's hard to think of a case where a transient oil slick would have invited regulatory action,' said McDonald, who believes the time and expense of bringing a case against a well-financed shipping company is prohibitive.
In European waters for example, despite EU pollution laws that sometimes surpass Marpol in stringency and satellite-based systems being utilised, enforcement remains uneven with limited penalties and few prosecutions, the European court of auditors warned in March.
'In our recent audit of EU actions tackling sea pollution by ships, we concluded that polluting ships can still slip through the net,' said Nikolaos Milionis, the ECA member responsible for the audit.
'In particular, we found that EU countries check fewer than half of the possible spills detected by the EU satellite-based system. In the end, they confirmed pollution in only 7% of the cases. This shows both limitations in the technology and in the means used by member states to check the alerts,' Milionis said.
The auditors concluded that pollution from ships was a serious problem and that with more than three-quarters of European seas estimated to have a pollution problem, the EU's zero-pollution ambition to protect people's health, biodiversity and fish stocks was out of reach.
In another new study of satellite images off the coast of six west African countries from 2021 to 2022, Atwood found that 16% of slicks, covering roughly the size of 28,800 football pitches, were from ships. In that same timeframe no incidents were recorded by international marine pollution authorities off the coasts of Benin, Ghana, Ivory Coast, Sierra Leone, Liberia and Togo.
Experts have warned these chronic spills are threatening sea life.
'All visible slicks should be considered harmful to the marine environment, especially given that trace quantities of oil are damaging to planktonic organisms, which form the base of the marine food web,' said O'Reilly.
Sign up to Down to Earth
The planet's most important stories. Get all the week's environment news - the good, the bad and the essential
after newsletter promotion
'Individually the volumes of oil are pretty small, nonetheless, when you add up all the ship traffic, and we should note that ship traffic and the occurrence of these oil slicks is increasing over time, the cumulative effect is certainly significant,' McDonald said.
Much of the pollution from ships comes from what is known as bilge dumping. Oil and potentially toxic liquids from the engine room of a ship accumulate in the lowest part of a ship, known as the bilge. Ships need to get rid of bilgewater because, if left unchecked, it can affect a ship's stability and be corrosive, leading to safety hazards. It can legally be released at sea if it is treated by an oily water separator, which large ships have onboard, but that does not always happen.
'Some vessels might be badly maintained and the bilge will be filling up constantly,' said a mariner who wishes to remain anonymous. 'It takes time to go through the separator, so to keep on top of it, the oil water separator is bypassed. Or the separator might be broken.'
Bilgewater could also be off-loaded at port for treatment, but this is costly.
'Commercial pressures in shipping are huge. It's all about profit and any savings you can make. Being in port is the most expensive time of the journey. There are port fees, pilotage fees, it's expensive and the less you do at port and the less time you spend there, the cheaper it is,' explained the mariner.
He also questioned whether there were enough inspectors at ports to check ships and scrutinise their oil logbooks.
A spokesperson for the International Maritime Organization (IMO) said: 'Oil and bilgewater operational discharges at sea by ships are regulated under the Marpol convention annex I. Ships must carry a mandatory oil record book, which should record all oil and sludge transfers and discharge, and allows for checks and monitoring by flag and port states … [which] have the remit and responsibility for implementation of IMO treaties.'
Ocean conservationists such as Tagholm want more action to be taken to clean up the shipping industry.
'Tankers, carrying oil and gas across the world, make up a third or more of all shipping,' he said. 'If we ended our addiction to fossil fuels – as we must to prevent climate breakdown – we would also halt the severe consequences of these spills, from disrupting the foundations of marine food chains.'
This story was produced in partnership with the Pulitzer Center's Ocean Reporting Network
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Telegraph
43 minutes ago
- Telegraph
Alzheimer's wonder drug delays disease for four years
Alzheimer's patients can stave off the progression of disease for four years with radical new treatments, The Telegraph can reveal. Trial findings show that some patients – who were given the drug lecanemab at an early stage and had little 'pathological' change to the brain – even saw improvements in their cognitive scores. The drug was licensed for use in the UK last year after trials found it was the first medication to slow progression of disease. Over 18 months, it was found to have slowed it by 5.7 months. The new findings, from a trial of 478 patients who stayed on the drug for four years, found an average delay of almost 11 months before their disease progressed to the next stage. Remarkable results were seen in a sub-group of patients who had low levels of tau, the protein that accumulates as Alzheimer's progresses. In total, 69 per cent of those in this group had no decline at all over four years, and 56 per cent saw an improvement in their cognitive scores. Prof Christopher Van Dyck, the director of the Alzheimer's Research unit at the Yale school of medicine and the study leader, said: 'The thing I really focus on is the time saved. You will get worse over time, but it will take longer to get there.' He said the findings, presented for manufacturers Eisai, made the case for starting early in treatment of Alzheimer's as 'people with the lowest pathology do tend to do the best'. Experts said the results – presented at the Alzheimer's Association International Conference in Toronto – offered hope that the new class of medicines could 'meaningfully change the course of the disease', not just slow decline in the short-term. They also said there was growing evidence to support earlier prescribing of such drugs, with trials planned shortly to see if similar medications, which appear to have fewer side effects, could one day be used preventively. About one million people in the UK suffer from dementia, with Alzheimer's disease the most common form. Lecanemab is part of a new class of medicines aimed at clearing amyloid plaques, the hallmark of Alzheimer's. Typically, patients with mild dementia see scores rise by between one and two points a year on scoring systems used to track the disease. But across the whole trial group, decline was measured at an increase of just 1.75 points over four years. Results from a separate trial of donanemab, a similar drug, also showed powerful results. The drug is normally given for 18 months, or until amyloid in the brain is cleared. Scientists tracked patients for a total of three years, including the time off the drug. The changes in dementia scores, compared with untreated patients, suggest that those prescribed donenamab had gained between six and 12 months before disease progressed. Dr Sheona Scales, the director of research at Alzheimer's Research UK said: 'These latest findings offer renewed hope that Alzheimer's treatments can meaningfully change the course of the disease, not just slow decline in the short term. 'New long-term data show that the benefits of donanemab may continue even after treatment ends, and people on lecanemab for up to four years maintained cognitive gains, with some even improving. Among those treated early with lecanemab and with low levels of tau, over half showed no decline after four years. 'This is the first wave of disease-modifying treatments for Alzheimer's and, while the progress is encouraging, there are still many pieces of the puzzle we don't yet have.' Dr Scales said studies were helping to address key questions about long-term benefits, but uncertainties remained over what happens in the brain when treatment stops and whether amyloid levels stay low long-term. 'As the evidence grows, it's vital that in the UK we continue to evaluate the potential benefit that the treatments could offer to people with Alzheimer's,' she added. Results from another trial earlier this week suggest that a third treatment called trontinemab, which works in a similar way, but is engineered to reduce side effects, could be the most powerful weapon yet against dementia. The study presented earlier this week found the treatment can clear the devastating plaques associated with Alzheimer's far more rapidly than any current licensed drug. The lack of side effects means it could be offered to large populations. This also means it could be offered at a far lower price than current medications, which require intense monitoring – including regular scans – meaning it is more likely to be funded by the NHS.


Daily Mail
2 hours ago
- Daily Mail
Elon Musk's brain chip company Neuralink to test implants in UK
Elon Musk 's brain implant company will launch a clinical study in Britain to test how its chips can allow severely paralysed patients to control everyday items with their thoughts. Neuralink is partnering with University College London Hospitals Trust and Newcastle Hospitals for the project, it said today. Those living with paralysis due to conditions such as spinal cord injuries and a nervous system disease called amyotrophic lateral sclerosis qualify for the study, the company revealed in a post on X. The firm began human trials on its brain implant last year after resolving safety concerns flagged by the US Food and Drug Administration. Five patients around the world with severe paralysis are using its device, according to Neuralink. They include a woman who has been paralysed for 20 years and has now regained the ability to use a computer. Audrey Crews, from Louisiana, revealed on X last month how she was now able to write her name on a computer screen thanks to Neuralink's implant. 'I tried writing my name for the first time in 20 years. I'm working on it,' Ms Crews posted during her first signature attempt since 2005. She was severely injured in a car accident aged 16, damaging two vertebrae in her neck and leaving her with no feeling in her arms and legs. Mr Musk, the CEO of SpaceX and Tesla, co-founded Neuralink in 2016 with a group of neuroscience, engineering, and robotics experts. Their goal was to merge human intelligence with artificial intelligence, treat brain disorders and potentially enhance human capabilities. The billionaire said in June that the chip technology had made 'an incredible amount of progress'. But he emphasised the company's cautious approach, adding: 'The reason we're not moving faster than we are is because we're taking great care with each individual to make sure we never miss - and, so far, we haven't.'


Telegraph
2 hours ago
- Telegraph
British patients to get Musk's Neuralink brain chip implants
British patients are to be implanted with Elon Musk's Neuralink brain chip in an attempt to allow paralysed people to control a smartphone with their thoughts. Mr Musk's start-up, which has already conducted tests in the US, said it was launching a clinical study in the UK with University College London Hospitals and Newcastle upon Tyne Hospitals NHS Foundation Trust after getting the green light from UK medical regulators. The trial will recruit seven patients whose movement is severely impaired from spinal cord injuries or neurological conditions, installing Neuralink's chip under their skull to communicate with a smartphone or tablet. The company's N1 chip – a so-called Brain-Computer Interface (BCI) – is about the size of a 10p coin and connects to the human brain with 128 threads that are thinner than a human hair. These threads connect 1,000 electrodes to the human brain that can read electrical signals generated by neural activity, turning these waves into keyboard strokes or cursor movements. Neuralink said: 'The launch of this study in Great Britain builds upon the successes of our trials in the US and marks an important step towards bringing our life-changing BCI technology to individuals with neurological disorders around the world.' Last year, Noland Arbaugh, from Arizona, became the first human to be implanted with Neuralink's brain chip. He has since demonstrated how the chip allows him to control a computer and play complicated video games. After his operation, however, around 85pc of the threads from his Neuralink chip lost their connection to his brain. The company was able to maintain a high level of performance using software updates to improve how the chip read his brain signals. While Neuralink is initially aimed at patients with serious health conditions, Mr Musk has long claimed that its chips could ultimately lead to a kind of human-AI 'symbiosis', boosting the brain power of otherwise healthy humans. He said on a podcast he expected hundreds of millions of people to have brain-chips installed, claiming it would give people 'superhuman abilities', allow them to 'upload your memories' or cure blindness. Neuralink has already begun work on trials in Canada and the UAE, although the UK is the first country in Europe to launch a study of the technology. It has been approved by the Medicines and Healthcare products Regulatory Agency. University College London said Neuralink's technology had the 'potential to transform the lives of individuals with neurological disorders around the world'. The operations will be undertaken using Neuralink's R1 surgical robot. Professor Harith Akram, a consultant neurosurgeon at the hospital, said the launch of the study 'represents a major milestone in the development of brain-computer interface technology, with the potential to transform the lives of people living with severe neurological disorders worldwide'. William Muirhead, a consultant neurosurgeon at the National Hospital for Neurology, said: 'This study reflects our commitment to pioneering therapies that restore function, independence, and communication in patients with profound neurological disability.'